I don't know about that. In this case, I don't understand what everyone is excited about.
There was no indication the drug did anything other than reduce contractility as advertised, but how does that alleviate the obstructive phenotype that they're going after? The genetic mutations driving the hypertrophy remain and are untouched by the drug, and if they show no remodeling of the ventricle / septum, then the obstruction will remain.
At this point I don't see how this drug is any different than giving someone a b-blocker to alleviate oHCM symptoms.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
